美国 · SEC FORM 4
Entrada Therapeutics, Inc.
TRDA · Nasdaq · CIK 0001689375 · Healthcare · Biotechnology
内部人信号
当前没有活跃买入信号
1 qualifying P purchase group
当前 180 天评分窗口
41 同一窗口内观察到的 Form 4 交易行
35 sales · 5 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2026-05-20 · Zeiher Bernhardt G · $29.3K
为什么没有活跃信号？
买入活动存在
近期买入1 qualifying line group(s)
近期卖出High
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLCTenPercentOwner
▼▼▼▼▼▼▼▼▼▼▼▼
EVNIN LUKE; Foley Todd; GADICKE ANSBERT; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM Asset Management Investors BV2014 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2014 (B), L.P.; MPM BioVentures 2014 GP LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014, L.P.TenPercentOwner
▼▼▼▼▼▼▼▼▼▼▼▼
PARMAR KUSHDirector
▼▼▼▼▼
5AM Opportunities I (GP), LLC; 5AM Opportunities I, L.P.; 5AM Partners V, LLC; 5AM Ventures V, L.P.; ROCKLAGE SCOTT M; Schwab Andrew J.TenPercentOwner
▼▼▼▼
WENTWORTH KORY JAMESChief Financial Officer
○
Sethuraman NatarajanPresident, Research & Develop.
○
● 买入▼ 卖出○ 其他
Showing the six most active owners; 3 additional owner(s) remain in Form 4 申报证据.
买方广度与集中度
合资格买方1
买入集中度100%最大买方： Zeiher Bernhardt G · $29.3K
聚集买入 · 15天1 insider峰值活动： 2026-05-20–2026-05-20
Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-05-20 · Zeiher Bernhardt G.
近期 Form 4 活动
17买入
44卖出
17其他 Form 4 交易行
32SEC 申报 · 365天
买入1 qualifying P line(s) · 180 days
卖出35 sale line(s) · 仅供背景
其他5 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 2,989,455
- 上期报告
- 2,744,145
- 日均成交量
- 303,169
- 回补天数
- 9.9
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-05-20 | Zeiher Bernhardt G | 买入 (P) | Common Stock | 5,000 | USD 5.86 | USD 29,300 | SEC 申报 ↗ |
| 2025-11-20 | BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC | 买入 (P) | Common Stock | 28,867 | USD 9.07 | USD 261,824 | SEC 申报 ↗ |
| 2025-11-12 | BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC | 买入 (P) | Common Stock | 100,736 | USD 7.76 | USD 781,447 | SEC 申报 ↗ |
| 2025-11-11 | BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC | 买入 (P) | Common Stock | 46,434 | USD 7.50 | USD 348,198 | SEC 申报 ↗ |
| 2025-11-10 | BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC | 买入 (P) | Common Stock | 30,874 | USD 7.21 | USD 222,634 | SEC 申报 ↗ |
| 2024-05-14 | KIM PETER S | 买入 (P) | Common Stock | 25,000 | USD 14.59 | USD 364,750 | SEC 申报 ↗ |
| 2024-05-14 | KIM PETER S | 买入 (P) | Common Stock | 25,000 | USD 14.59 | USD 364,750 | SEC 申报 ↗ |
| 2024-05-13 | KIM PETER S | 买入 (P) | Common Stock | 25,000 | USD 14.68 | USD 367,000 | SEC 申报 ↗ |
| 2024-05-09 | KIM PETER S | 买入 (P) | Common Stock | 2,200 | USD 14.25 | USD 31,350 | SEC 申报 ↗ |
| 2024-05-08 | KIM PETER S | 买入 (P) | Common Stock | 2,276 | USD 14.04 | USD 31,955 | SEC 申报 ↗ |
| 2024-04-08 | KIM PETER S | 买入 (P) | Common Stock | 2,600 | USD 13.57 | USD 35,282 | SEC 申报 ↗ |
| 2024-03-28 | KIM PETER S | 买入 (P) | Common Stock | 1,512 | USD 13.75 | USD 20,790 | SEC 申报 ↗ |
| 2024-03-26 | KIM PETER S | 买入 (P) | Common Stock | 2,750 | USD 13.64 | USD 37,510 | SEC 申报 ↗ |
| 2024-03-25 | KIM PETER S | 买入 (P) | Common Stock | 3,180 | USD 13.36 | USD 42,485 | SEC 申报 ↗ |
| 2024-03-22 | KIM PETER S | 买入 (P) | Common Stock | 3,118 | USD 13.76 | USD 42,904 | SEC 申报 ↗ |
Form 4 申报证据
78 transaction lines in the latest 365-day window; 438 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-09 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC | 卖出 (S) | Common Stock | 28,837 | USD 7.13 | USD 205,608 | SEC 申报 ↗ |
| 2026-09-09 | EVNIN LUKE; Foley Todd; GADICKE ANSBERT; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM Asset Management Investors BV2014 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2014 (B), L.P.; MPM BioVentures 2014 GP LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014, L.P. | 卖出 (S) | Common Stock | 28,837 | USD 7.13 | USD 205,608 | SEC 申报 ↗ |
| 2026-09-08 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC | 卖出 (S) | Common Stock | 192,500 | USD 7.41 | USD 1,426,425 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-09 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC | 卖出 (S) | Common Stock | 28,837 | USD 7.13 | USD 205,608 | SEC 申报 ↗ |
| 2026-09-09 | EVNIN LUKE; Foley Todd; GADICKE ANSBERT; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM Asset Management Investors BV2014 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2014 (B), L.P.; MPM BioVentures 2014 GP LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014, L.P. | 卖出 (S) | Common Stock | 28,837 | USD 7.13 | USD 205,608 | SEC 申报 ↗ |
| 2026-09-08 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC | 卖出 (S) | Common Stock | 192,500 | USD 7.41 | USD 1,426,425 | SEC 申报 ↗ |
| 2026-09-08 | EVNIN LUKE; Foley Todd; GADICKE ANSBERT; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM Asset Management Investors BV2014 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2014 (B), L.P.; MPM BioVentures 2014 GP LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014, L.P. | 卖出 (S) | Common Stock | 192,500 | USD 7.41 | USD 1,426,425 | SEC 申报 ↗ |
| 2026-09-04 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC | 卖出 (S) | Common Stock | 38,500 | USD 7.11 | USD 273,735 | SEC 申报 ↗ |
| 2026-09-04 | EVNIN LUKE; Foley Todd; GADICKE ANSBERT; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM Asset Management Investors BV2014 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2014 (B), L.P.; MPM BioVentures 2014 GP LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014, L.P. | 卖出 (S) | Common Stock | 38,500 | USD 7.11 | USD 273,735 | SEC 申报 ↗ |
| 2026-09-03 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC | 卖出 (S) | Common Stock | 32,263 | USD 7.17 | USD 231,326 | SEC 申报 ↗ |
| 2026-09-03 | EVNIN LUKE; Foley Todd; GADICKE ANSBERT; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM Asset Management Investors BV2014 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2014 (B), L.P.; MPM BioVentures 2014 GP LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014, L.P. | 卖出 (S) | Common Stock | 32,263 | USD 7.17 | USD 231,326 | SEC 申报 ↗ |
| 2026-09-02 | WENTWORTH KORY JAMES | 代扣税 (F) | Common Stock | 1,733 | USD 7.14 | USD 12,374 | SEC 申报 ↗ |
| 2026-09-02 | Sethuraman Natarajan | 代扣税 (F) | Common Stock | 2,079 | USD 7.14 | USD 14,844 | SEC 申报 ↗ |
| 2026-09-02 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC | 卖出 (S) | Common Stock | 25,131 | USD 7.19 | USD 180,692 | SEC 申报 ↗ |
| 2026-09-02 | EVNIN LUKE; Foley Todd; GADICKE ANSBERT; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM Asset Management Investors BV2014 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2014 (B), L.P.; MPM BioVentures 2014 GP LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014, L.P. | 卖出 (S) | Common Stock | 25,131 | USD 7.19 | USD 180,692 | SEC 申报 ↗ |
| 2026-09-02 | Dowden Nathan J | 代扣税 (F) | Common Stock | 2,528 | USD 7.14 | USD 18,050 | SEC 申报 ↗ |
| 2026-09-02 | Doshi Dipal | 代扣税 (F) | Common Stock | 8,724 | USD 7.14 | USD 62,289 | SEC 申报 ↗ |
| 2026-09-01 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC | 卖出 (S) | Common Stock | 29,088 | USD 7.06 | USD 205,361 | SEC 申报 ↗ |
| 2026-09-01 | EVNIN LUKE; Foley Todd; GADICKE ANSBERT; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM Asset Management Investors BV2014 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2014 (B), L.P.; MPM BioVentures 2014 GP LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014, L.P. | 卖出 (S) | Common Stock | 29,088 | USD 7.06 | USD 205,361 | SEC 申报 ↗ |
| 2026-08-31 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC | 卖出 (S) | Common Stock | 44,259 | USD 6.99 | USD 309,370 | SEC 申报 ↗ |
| 2026-08-31 | EVNIN LUKE; Foley Todd; GADICKE ANSBERT; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM Asset Management Investors BV2014 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2014 (B), L.P.; MPM BioVentures 2014 GP LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014, L.P. | 卖出 (S) | Common Stock | 44,259 | USD 6.99 | USD 309,370 | SEC 申报 ↗ |
| 2026-08-28 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC | 卖出 (S) | Common Stock | 3,733 | USD 7.01 | USD 26,168 | SEC 申报 ↗ |
| 2026-08-28 | EVNIN LUKE; Foley Todd; GADICKE ANSBERT; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM Asset Management Investors BV2014 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2014 (B), L.P.; MPM BioVentures 2014 GP LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014, L.P. | 卖出 (S) | Common Stock | 3,733 | USD 7.01 | USD 26,168 | SEC 申报 ↗ |
| 2026-08-27 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC | 卖出 (S) | Common Stock | 38,922 | USD 7.20 | USD 280,238 | SEC 申报 ↗ |
| 2026-08-27 | EVNIN LUKE; Foley Todd; GADICKE ANSBERT; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM Asset Management Investors BV2014 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2014 (B), L.P.; MPM BioVentures 2014 GP LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014, L.P. | 卖出 (S) | Common Stock | 38,922 | USD 7.20 | USD 280,238 | SEC 申报 ↗ |
| 2026-08-26 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC | 卖出 (S) | Common Stock | 14,569 | USD 7.06 | USD 102,857 | SEC 申报 ↗ |
| 2026-08-26 | EVNIN LUKE; Foley Todd; GADICKE ANSBERT; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM Asset Management Investors BV2014 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2014 (B), L.P.; MPM BioVentures 2014 GP LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014, L.P. | 卖出 (S) | Common Stock | 14,569 | USD 7.06 | USD 102,857 | SEC 申报 ↗ |
| 2026-08-25 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC | 卖出 (S) | Common Stock | 26,522 | USD 7.54 | USD 199,976 | SEC 申报 ↗ |
| 2026-08-25 | EVNIN LUKE; Foley Todd; GADICKE ANSBERT; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM Asset Management Investors BV2014 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2014 (B), L.P.; MPM BioVentures 2014 GP LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014, L.P. | 卖出 (S) | Common Stock | 26,522 | USD 7.54 | USD 199,976 | SEC 申报 ↗ |
| 2026-08-24 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC | 卖出 (S) | Common Stock | 21,623 | USD 7.34 | USD 158,713 | SEC 申报 ↗ |
| 2026-08-24 | EVNIN LUKE; Foley Todd; GADICKE ANSBERT; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM Asset Management Investors BV2014 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2014 (B), L.P.; MPM BioVentures 2014 GP LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014, L.P. | 卖出 (S) | Common Stock | 21,623 | USD 7.34 | USD 158,713 | SEC 申报 ↗ |
| 2026-08-10 | PARMAR KUSH | 卖出 (S) | Common Stock | 92,444 | USD 7.00 | USD 647,108 | SEC 申报 ↗ |
| 2026-08-07 | PARMAR KUSH | 卖出 (S) | Common Stock | 52,317 | USD 6.85 | USD 358,371 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | TRDA |
| CIK | 0001689375 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 438 transaction lines from 2021-11-02 to 2026-09-09 61 P purchase lines · 217 S sale lines · 160 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.